Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytokine-Guided Risk Stratification for Pediatric HLH
NCT05491304Phase 4Recruiting
- Sponsor
- Children's Hospital, Zhejiang University School of Medicine
- Start
- Sep 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ruxolitinib in hemophagocytic lymphohistiocytosis (HLH), sponsored by Children's Hospital, Zhejiang University School of Medicine. Started Sep 2022; status: recruiting.
02
Drugs
03
Conditions
hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT05491304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05491304.